Anthrax

Anthrax is a serious, acutely life-threatening zoonotic infectious disease caused by the spore-forming bacterium Bacillus anthracis.

It primarily infects domesticated and wild herbivorous mammals—predominantly cattle, sheep, goats, buffaloes, and horses—which ingest or inhale bacterial endospores from contaminated pastures, soil, or water. Humans are incidental hosts who contract the illness through occupational contact with infected animals, handling contaminated animal by-products (hides, skins, wool, bones, hair), consuming diseased carcass meat, or via deliberate weaponized aerosol dissemination.

• Endemic Pastoral Settings: In East Africa, particularly along the pastoral "cattle corridors" of Uganda (e.g., Arua, Madi-Okollo, Kween, Isingiro, Kiruhura, and the Queen Elizabeth National Park wildlife ecosystem), sporadic outbreaks frequently occur among livestock and wild herbivores (hippos, buffaloes). Human outbreaks almost invariably follow the illicit skinning, butchering, and domestic consumption of animals that died suddenly of unexplained illnesses.
• Occupational Risk Profiles: High-risk occupational groups include veterinarians, abattoir workers, slaughterhouse butchers, tanners, wool sorters, livestock farmers, and wildlife rangers.
• Category A Bioterrorism Agent: Bacillus anthracis is designated by global defense and public health authorities as a top-tier Category A Bioterrorism Agent. Its spores can be manufactured in high concentrations, remain viable in aerosol clouds over long distances, survive indefinitely in storage, and cause inhalation anthrax—a clinical form associated with overwhelming septicemia, rapid collapse, and catastrophic mortality exceeding 80–90% without rapid, specialized medical intervention.

• Morphology: Large, rectangular, square-ended, Gram-positive, non-motile, facultatively anaerobic rod (measuring 1–1.5 μm wide by 3–10 μm long). Under light microscopy, the vegetative bacilli appear characteristically in long, jointed chains resembling "boxcars" or "trains of bamboo."
• Spore Dynamics (The Vegetative vs. Spore Cycle):
  • Vegetative Cells: Inside an infected animal or human host, the bacteria multiply rapidly in tissue fluids and blood. They are capsulated, metabolically active, highly sensitive to drying and common disinfectants, and do not sporulate inside the living body or intact unopened carcass due to high carbon dioxide and low oxygen concentrations.
  • Sporulation: When an infected carcass is cut open, butchered, or bled, the vegetative cells are suddenly exposed to ambient atmospheric oxygen (room air). This environmental shift triggers rapid sporulation, transforming vegetative cells into dormant, oval central endospores.
  • Environmental Resilience: Anthrax endospores are among the hardiest biological structures known on Earth. Lacking metabolic activity, they resist boiling, desiccation, direct sunlight, ultraviolet (UV) radiation, freezing, and standard chemical disinfectants (including alcohol-based hand rubs). They persist viable in alkaline, calcium-rich soils for decades, periodically surfacing after heavy rains, floods, or agricultural excavation.
  • Germination: When an endospore enters a living host (rich in moisture, neutral pH, glucose, and essential amino acids), it is phagocytosed by local macrophages, rapidly sheds its protective spore coat, and germinates back into lethal vegetative bacteria.

Virulence in B. anthracis is mediated entirely by two distinct virulence plasmids: pXO2 (encoding the antiphagocytic capsule) and pXO1 (encoding the tripartite exotoxin complex):

Unlike almost all other bacterial capsules composed of polysaccharides, the capsule of B. anthracis is a pure polypeptide composed of repeating polymers of poly-D-glutamic acid. It is strongly negatively charged, rendering the vegetative bacillus completely non-immunogenic and immune to complement-mediated phagocytosis by host neutrophils and circulating reticuloendothelial macrophages. This enables unhindered intravascular multiplication up to densities exceeding 10⁸ bacilli per milliliter of blood.

The bacterium secretes three distinct, non-toxic monomeric proteins that assemble on host cell surfaces to form two devastating binary toxins:

1. Protective Antigen (PA - 83 kDa): The binding component and master molecular "key" for both toxins. PA binds to specific host cell-surface receptors (Capillary Morphogenesis Protein 2 [CMG2] and Tumor Endothelial Marker 8 [TEM8]). Cell-surface furin-like proteases cleave PA into an active PA63 fragment, which self-assembles into a heptameric/octameric "pre-pore" ring. This ring competitively docks either Edema Factor (EF) or Lethal Factor (LF), triggering receptor-mediated endocytosis into host cell endosomes. Acidification of the endosome causes conformational insertion of the PA pore into the endosomal membrane, releasing EF and LF directly into the host cytoplasm.
   Clinical Pearl: Because PA is the essential delivery vehicle for both toxins, it serves as the primary target for human anthrax vaccines (BioThrax/AVA) and modern therapeutic monoclonal antitoxins (Raxibacumab and Obiltoxaximab).
2. Edema Factor (EF - 89 kDa) → Forming Edema Toxin (EdTx): A highly potent, calmodulin-dependent adenylate cyclase. Once inside the host cytosol, EF binds intracellular calmodulin, increasing enzymatic activity more than 1,000-fold to convert adenosine triphosphate (ATP) into excessive, uncontrolled levels of cyclic adenosine monophosphate (cAMP). Massive cAMP elevations abolish normal intracellular ion homeostasis, downregulate endothelial cadherin junctions, and drive rapid extravasation of water and chloride into interstitial tissues. This produces the massive, non-pitting, gelatinous edema characteristic of all forms of anthrax and paralyzes the bactericidal oxidative burst of neutrophils.
3. Lethal Factor (LF - 90 kDa) → Forming Lethal Toxin (LeTx): A zinc-dependent metalloprotease that selectively cleaves and inactivates the amino-terminal domains of Mitogen-Activated Protein Kinase Kinases (MAPKK / MEKs 1, 2, 3, 4, 6, and 7). Inactivating this central signaling cascade halts vital transcription pathways, inducing widespread apoptotic cell death of monocytes, macrophages, and dendritic cells. Furthermore, LeTx damages endothelial linings, induces massive mitochondrial dysfunction, provokes systemic vascular collapse (refractory distributive shock), activates catastrophic intravascular thrombosis (DIC), and precipitates sudden cardiorespiratory failure.

Anthrax presents in distinct clinical forms defined entirely by the anatomical portal of entry:

• Incidence: Accounts for approximately 95% of all naturally acquired human anthrax cases globally.
• Transmission: Inoculation of endospores through small cuts, micro-abrasions, insect bites, or open eczema while skinning, slaughtering, shearing, butchering, or handling animal carcasses, raw hides, wool, leather, or bone meal. Most frequently occurs on exposed anatomical zones: hands, forearms, neck, and face.
• Incubation Period: 1 to 7 days (typically 2 to 5 days; occasionally up to 12 days).
• Sequential Lesion Evolution:
  1. Day 1–2 (Papular Stage): Emergence of an intensely pruritic, painless, small, red-to-violaceous papule closely mimicking an innocuous insect bite.
  2. Day 2–3 (Vesicular Stage): The papule rapidly enlarges and evolves into a tense, fluid-filled blister (vesicle) or a ring of tiny satellite vesicles containing clear, straw-colored, or serosanguinous fluid packed with thousands of vegetative bacilli.
  3. Day 3–5 (Ulcerative Stage): The central vesicle spontaneously ruptures, weeping serosanguinous discharge, eroding into a sharply demarcated, painless, shallow ulcer with an indurated, raised, violaceous border.
  4. Day 5–7 (The Classic Eschar): The ulcer floor rapidly undergoes central coagulative necrosis, transforming into a thick, leather-like, jet-black, sunken necrotic crust termed a Black Eschar (from the Greek anthrakis, meaning coal).
  5. Surrounding Features: The eschar is surrounded by a prominent collar of striking, gelatinous, non-pitting, painless edema driven by Edema Toxin. Marked, painful regional lymphadenopathy develops. Over 2 to 6 weeks, the dry eschar separates, sloughs off, and leaves a permanent scarred depression.
• Pain Disproportion: A critical hallmark of cutaneous anthrax is that the central ulcer and black eschar are completely painless and non-purulent (no pus), unless superinfected by secondary bacteria like Staphylococcus aureus.
• Malignant Edema of the Head and Neck: When cutaneous lesions occur on the face or neck, the edema can spread rapidly across the cervical fascial planes, compressing the larynx and trachea, precipitating acute, fatal upper airway obstruction (stridor), and rapidly advancing into systemic toxemia.
• Prognosis: If untreated, up to 20% of cutaneous anthrax cases result in fatal systemic bacteremia and shock. With prompt, appropriate antibiotic therapy, mortality drops to less than 1%.

• Incidence: Historically rare; associated with processing contaminated wool, mohair, or goat skins in enclosed factories. Primary concern in aerosolized biological warfare.
• Transmission: Inhalation of invisible aerosolized spore nuclei (optimal droplet size: 1 to 5 μm) directly into the terminal alveoli. Spores are ingested by alveolar macrophages and transported via lymphatic drainage into the mediastinal and tracheobronchial lymph nodes, where they germinate. Inhalation anthrax is not a primary pneumonia, but a severe, necrotizing, hemorrhagic mediastinitis.
• Incubation Period: 1 to 60 days (typically 1 to 7 days). Endospores can lay dormant inside deep lung macrophages for up to 8–10 weeks before initiating delayed germination, necessitating prolonged antibiotic courses.
• Biphasic Clinical Course:
  • 1. Early Prodromal Phase (Days 1–4): Insidious, non-specific presentation closely mimicking a common viral influenza illness: low-grade fever, malaise, extreme fatigue, dry non-productive cough, mild substernal chest ache, and diffuse myalgia. Sometimes punctuated by transient subjective improvement that falsely reassures the patient.
  • 2. Fulminant / Toxic Phase: Abrupt, catastrophic clinical deterioration occurring within hours: spiking hyperpyrexia, profound dyspnea, diaphoresis, central cyanosis, stridor, respiratory exhaustion, severe hypoxia, and massive hemorrhagic pleural effusions. Massive edema of the mediastinum compresses the superior vena cava and heart, causing rapid development of refractory hypotensive septic shock.
  • Hemorrhagic Meningitis: In up to 50% of inhalation anthrax cases, hematogenous seeding to the central nervous system produces acute, rapidly fatal hemorrhagic leptomeningitis, manifesting as sudden agonizing headache, meningismus, delirium, repeated seizures, and coma.
• Prognosis: Even with modern mechanical ventilation, continuous thoracostomy drainage, multi-agent IV bactericidal antibiotics, and antitoxins, mortality remains high (approximately 40% to 50%). Untreated inhalation anthrax carries a mortality rate approaching 95% to 100% within 24 to 48 hours of fulminant onset.

• Incidence: Occurs almost exclusively following the consumption of insufficiently cooked meat or broth derived from livestock that died acutely of anthrax.
• Incubation Period: 1 to 7 days (typically 2 to 5 days).
• Clinical Subtypes:
  • 1. Oropharyngeal Anthrax: Spores inoculate the oral cavity and pharynx. Presents with severe sore throat, dysphagia (inability to swallow saliva), high fever, marked hoarseness, unilateral swelling of the soft palate/tonsil covered by an adherent pseudomembranous necrotic ulcer, and massive bilateral cervical and submandibular lymphadenopathy with extensive neck edema. Can progress rapidly to upper airway compromise and asphyxiation.
  • 2. Intestinal Anthrax: Spores germinate primarily in the terminal ileum and cecum, where they penetrate the mucosal barrier and lodge within the mesenteric lymph nodes.
    • Early Signs: Severe nausea, profound anorexia, projectile vomiting, and high fever accompanied by generalized abdominal cramping.
    • Fulminant Signs: Massive mucosal ulceration and bowel wall necrosis lead to severe hematemesis (vomiting blood), profuse, foul-smelling melena or frank bloody diarrhea, and rapid development of tender, tense, massive hemorrhagic ascites. Bowel perforation, peritonitis, septic shock, and multi-organ failure quickly follow.
• Prognosis: High case fatality rate of 25% to 60%, frequently driven by delayed diagnosis due to clinical mimicry of acute surgical emergencies (acute appendicitis, intussusception, perforated peptic ulcer).

• Epidemiology: Identified among people who inject drugs (PWID) in Northern Europe, caused by injecting heroin contaminated with soil-derived anthrax spores.
• Clinical Distinctions: Characterized by severe, progressive deep soft-tissue infection (necrotizing fasciitis, massive myonecrosis, and extensive subcutaneous edema). Classically, the painless black eschar is COMPLETELY ABSENT. Patients present with profound systemic toxemia, compartment syndrome requiring emergency fasciotomy, internal abscesses, and high mortality rates (~35%).

A definitive diagnosis requires high clinical suspicion combined with rapid microbiological, molecular, and radiological confirmation. All laboratory personnel handling suspected specimens must be alerted beforehand to observe strict Biosafety Level 3 (BSL-3) containment precautions to prevent laboratory-acquired inhalation anthrax.

• Immediate Empiric Initiation: Antibiotic therapy must be started immediately upon clinical suspicion. Any delay while awaiting laboratory culture results dramatically worsens mortality, particularly in inhalation and gastrointestinal disease.
• Bactericidal Multi-Drug Combinations: For systemic, inhalation, gastrointestinal, or complicated cutaneous disease, single-drug therapy is contraindicated. Protocols require at least two to three synergistic antibiotics from different classes: at least one bactericidal agent with intracellular and tissue penetration, combined with a protein synthesis inhibitor to immediately shut down bacterial exotoxin production.
• Antitoxin Administration: Antibiotics kill bacteria but have no effect on circulating exotoxins already bound to host receptors. Circulating free toxins must be neutralized using monoclonal or polyclonal antitoxins.

Defined as mild, localized skin lesions without signs of systemic toxicity, extensive edema, or head/neck involvement:

Mandates immediate admission to an Intensive Care Unit (ICU) and administration of a Triple-Agent Intravenous Antibiotic Regimen for at least 14 days, followed by oral step-down therapy to complete 60 days:

1. Primary Bactericidal Agent (Fluoroquinolone):
   • Ciprofloxacin: 400 mg IV every 8 hours in adults (children: 10–15 mg/kg IV q8–12h, max 400 mg/dose).
   • Alternatives: Levofloxacin (750 mg IV every 24 hours) OR Moxifloxacin (400 mg IV every 24 hours).
2. Protein Synthesis Inhibitor (Toxin-Suppressing Agent):
   • Clindamycin: 900 mg IV every 8 hours (children: 10–13 mg/kg IV q8h). Directly halts the ribosomal synthesis of Protective Antigen, Edema Factor, and Lethal Factor.
   • Alternative: Linezolid: 600 mg IV every 12 hours. Excellent tissue and CNS penetration, potent protein synthesis inhibition.
3. Third Agent (with Strong CNS / Beta-Lactam Coverage):
   • Meropenem: 2,000 mg IV every 8 hours (children: 40 mg/kg IV q8h, max 2g). Essential because of high blood-brain barrier penetration to treat or prevent hemorrhagic anthrax meningitis.
   • Alternatives (if penicillin-susceptible): Aqueous Penicillin G (4 million units IV every 4 hours) OR Ampicillin (2–3 g IV every 4 hours) OR Vancomycin (15–20 mg/kg IV every 8–12 hours, targeting trough levels of 15–20 μg/mL).

Indicated as an adjunct to intravenous antibiotics in all patients with confirmed or strongly suspected systemic, inhalation, or severe gastrointestinal anthrax:

• Raxibacumab: A recombinant human IgG1λ monoclonal antibody that binds with high affinity to the Protective Antigen (PA) monomer and heptamer, preventing it from binding to host cell receptors CMG2/TEM8. Dose: 40 mg/kg IV single infusion administered over 2 hours and 15 minutes. Pre-medicate with diphenhydramine 30 minutes prior to infusion to prevent infusion reactions.
• Obiltoxaximab: A chimeric human-murine monoclonal antibody targeting PA with comparable efficacy to Raxibacumab. Dose: 16 mg/kg IV single infusion over 90 minutes.
• Anthrax Immune Globulin Intravenous (AIGIV - Emergent BioSolutions): A human polyclonal immunoglobulin prepared from the plasma of healthy individuals immunized with BioThrax. Contains polyclonal antibodies that neutralize PA, EF, and LF. Dose: 420 units IV single infusion for adults.

• Aggressive Pleural Effusion Drainage: Inhalation anthrax effusions are voluminous, rapidly recurrent, serosanguinous, and rich in inflammatory mediators. Early placement of large-bore chest tubes (thoracostomy) with continuous drainage significantly relieves pulmonary compression and accelerates clinical recovery.
• Hemodynamic Shock Management: Capillary leakage driven by Edema Toxin and Lethal Toxin causes massive intravascular fluid shifts into interstitial spaces. Patients require rapid, monitored crystalloid resuscitation (Ringer's Lactate) combined with early administration of vasopressors (Norepinephrine or Vasopressin) to maintain mean arterial pressure (MAP ≥ 65 mmHg). Avoid fluid overload leading to pulmonary edema.
• Adjunctive Corticosteroid Therapy: Systemic corticosteroids (e.g., Intravenous Dexamethasone 10 mg every 6 hours or Methylprednisolone) are indicated for severe extensive edema of the head and neck threatening airway patency, life-threatening mass effect from hemorrhagic mediastinitis, or documented anthrax meningitis.

Patients with anthrax require rigorous critical care, protective barrier precautions, respiratory monitoring, hemodynamic support, and continuous patient education.

• Refractory Septic Shock & Systemic Toxemia: Driven by Lethal Toxin and massive systemic cytokine release, causing profound vascular smooth muscle paralysis, refractory hypotension, severe lactic acidosis, and multi-organ dysfunction syndrome (MODS).
• Anthrax Hemorrhagic Leptomeningitis: A dreaded, highly fatal complication occurring in up to 50% of systemic/inhalation cases. Characterized by extensive necrotic destruction of cerebral vessels, subarachnoid hemorrhage ("cardinal's cap" appearance on post-mortem brain examination), cerebral edema, status epilepticus, and death within 24 to 48 hours.
• Acute Upper Airway Obstruction & Asphyxiation: Extensive malignant edema crossing the deep cervical fascia in facial/neck cutaneous anthrax or severe oropharyngeal anthrax, leading to acute supraglottic swelling, laryngeal closure, and fatal suffocation without emergency tracheostomy.
• Tension Hemothorax & Massive Pleural Effusion: Rapid accumulation of liters of bloody, toxin-rich fluid within the pleural cavity, compressing the lung parenchyma, displacing the mediastinum, and leading to acute hypoxic respiratory arrest.
• Disseminated Intravascular Coagulation (DIC): Consumption coagulopathy triggered by widespread endothelial damage, leading to massive internal hemorrhage (hematemesis, melena, retroperitoneal bleeding) alongside microvascular thromboses.
• Bowel Gangrene, Perforation & Peritonitis: Deep necrotic ulceration across the terminal ileum and mesenteric ischemia leading to acute full-thickness bowel perforation, fecal peritonitis, and septic shock.

Because human anthrax is entirely dependent on animal disease, control of human anthrax requires breaking the transmission cycle at the livestock and soil level:

1. Safe Carcass Disposal (The Golden Rule):
   • NEVER OPEN OR CONDUCT A POST-MORTEM (NECROPSY) ON AN ANIMAL SUSPECTED OF DYING OF ANTHRAX. Vegetative bacilli inside an intact, unopened carcass are rapidly destroyed within days by anaerobic putrefactive bacteria. Opening the carcass exposes the blood to ambient oxygen, triggering immediate, massive sporulation and permanently contaminating the soil.
   • Deep Burial Protocol: The unopened carcass, along with blood-soiled topsoil and bedding, must be buried in a pit at least 2 meters (6.5 feet) deep, positioned above the water table, and covered generously with quicklime (calcium oxide) or 10% formalin before filling with soil. The burial site must be fenced off to prevent scavenger access.
   • Incineration: Complete, high-temperature thermal destruction using a closed commercial incinerator or specially designed biohazard pit under veterinary supervision. Open burning on firewood is discouraged as incomplete combustion can create thermal plumes that aerosolize viable spores.
2. Livestock Quarantine & Mass Vaccination:
   • Immediate imposition of strict veterinary quarantines prohibiting the movement, trade, or slaughter of livestock within a 15-kilometer radius of a confirmed animal case.
   • Annual pre-season mass vaccination of all herds (cattle, goats, sheep) in endemic districts using the Sterne strain live attenuated non-capsulated vaccine (34F2). Provides robust immunity lasting up to 12 months.
3. Prohibition of Carcass Consumption: Enforce strict municipal and public health laws penalizing the salvaging, selling, butchering, or eating of dead livestock. Meat inspection at abattoirs must screen for anthrax signs (unclotted dark blood oozing from natural body orifices—mouth, nostrils, anus; absence of rigor mortis; marked splenomegaly).

Indicated for individuals with confirmed or suspected aerosol exposure to B. anthracis spores (e.g., in a bioterrorism incident) or direct exposure to infectious tissues (butchering a confirmed anthrax carcass):

Pre-exposure vaccination with BioThrax (Anthrax Vaccine Adsorbed - AVA) is recommended for groups at continuous high risk of exposure: military personnel deployed to high-threat biological warfare zones, laboratory scientists handling virulent B. anthracis cultures, and workers processing animal hides, wool, and bone meal imported from high-endemic areas. Administered intramuscularly at 0 and 1 month, with booster doses at 6, 12, and 18 months, followed by annual boosters.

• Doctors Revision Uganda. Clinical Guide: Anthrax Etiology, Clinical Presentation, Diagnostics, Management & One Health Prevention. Available from: https://doctorsrevisionuganda.com/clinical-guide/anthrax/.
• Ministry of Health Uganda. National Technical Guidelines for Integrated Disease Surveillance and Response (IDSR). 3rd Edition. Kampala: Ministry of Health; 2021.
• World Health Organization (WHO), Food and Agriculture Organization (FAO), World Organisation for Animal Health (WOAH). Anthrax in Humans and Animals. 4th Edition. Geneva: World Health Organization; 2008.
• Centers for Disease Control and Prevention (CDC). Clinical Framework for the Treatment of Human Anthrax. MMWR Recommendations and Reports; 2014;63(RR-04):1-14.
• Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management. JAMA. 2002;287(17):2236–2252.
• Uganda Wildlife Authority (UWA) & Ministry of Agriculture, Animal Industry and Fisheries (MAAIF). Anthrax Surveillance and Outbreak Response Protocols in Livestock-Wildlife Interfaces. Entebbe, Uganda.